FDA Real-Time Surveillance Not Practical For All Drugs, CDER’s Safety Surveillance Chief Says

Gerald Dal Pan indicated in an interview that the agency's safety systems as now constituted are generating the data needed and that so-called real-time surveillance, which is in place for COVID-19 vaccines and therapeutics, is not practical for all approved products.

surveillance
FDA official says devoting resources to real-time surveillance of all approved drugs would not be useful. • Source: Shutterstock

Real-time surveillance for all approved drugs likely is not realistic or advisable for the US Food and Drug Administration, but can be switched on when necessary, Gerald Dal Pan, the director of the agency’s Office of Surveillance and Epidemiology, told the Pink Sheet in a recent interview.

The FDA has been conducting near real-time surveillance in specific situations for some time and Dal Pan indicated a selective...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet